Silence Therapeutics (Silence Therapeutics) Price-to-Tangible-Book : 77.54 (As of Apr. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Price-to-Tangible-Book?

As of today (2024-04-29), Silence Therapeutics's share price is $22.10. Silence Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.29. Hence, Silence Therapeutics's Price to Tangible Book Ratio of today is 77.54.

The historical rank and industry rank for Silence Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

SLN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.32 Med: 10.41 Max: 550
Current: 81.85

During the past 13 years, Silence Therapeutics's highest Price to Tangible Book Ratio was 550.00. The lowest was 1.32. And the median was 10.41.

SLN's Price-to-Tangible-Book is ranked worse than
99.1% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs SLN: 81.85

A closely related ratio is called PB Ratio. As of today, Silence Therapeutics's share price is $22.10. Silence Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.55. Hence, Silence Therapeutics's P/B Ratio of today is 40.55.

Silence Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Silence Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Price-to-Tangible-Book Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

500.00

597.25

32.73

60.95

Silence Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															32.73	22.14	38.19	25.84	60.95

Competitive Comparison of Silence Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Silence Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Price-to-Tangible-Book falls into.

Silence Therapeutics Price-to-Tangible-Book Calculation

Silence Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	22.10	/	0.285
	=	77.54

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Silence Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.